This website uses cookies to ensure you get the best experience. By continuing to browse the site, you agree to our use of cookies.

January Investment Report 2024

Biggest Seed, Series A-E and Venture Investments within Oncology January 2024.

View the report at the bottom of this page.

January 2024 Snapshot:

Total Investment for Oncology Biotechs

177 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 3,843,000,000.00 total true investment received in USA and EU within the Oncology sector in January 2024 across 38 different biotechs.

Some Notable True Oncology Investments

✅Accent Therapeutics - $750,00,000(Series C): 3x Preclinical, and IND-Enabling for oncology trials

✅Ratio Therapeutics - $ 50,000,000 (Series B): first patient dosed in Phase I study evaluating a novel FAP-Targeted radiopharmaceutical for PET imaging 

✅ GlycoEra - (Undisclosed Amount -Series A): target selection for oncology phase trial, lead ID, 2x pre-lead ID, and target selection for autoimmune diseases 

✅ Plus 30+ companies in the report.

Seen some big exits by RayzeBio and POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company end of December. Some big Series Cs and an IPO from Immatics (one of the best companies in the world, but I might be bias) in this report. Also another 3bn exit from MorphoSys (Feb).

Download the report here

Subscribe and recieve exclusive bonuses, tips and resources
Last name
Thank you! You've now subscribed to our mailing list. You'll receive exclusive bonuses, tips and resources directly to your inbox.
Oops! Something went wrong while submitting the form.